logo-loader
Pressure BioSciences Inc.

Pressure BioSciences' PCT technology highlighted in a pair of medical journal articles

Scientists in China and Australia published findings that showcased PCT’s ability to discover biomarkers associated with cancer in preserved tissue samples

Doctor with book
Pressure’s PCT technology employs alternating cycles of hydrostatic pressure to safely control biomolecular interactions

Pressure BioSciences Inc’s  (OTCMKTS:PBIO) said its signature Pressure Cycling Technology (PCT) platform has been highlighted in a pair of recent medical journal articles.

In a statement on Tuesday, the company noted that teams of scientists in China and Australia published findings that showcased PCT’s ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

Preserved samples, known as formalin-fixed paraffin-embedded (FFPE) samples, are useful for retrospective study of disease progression and therapy responses because the outcomes for the sample’s patient is already known. 

Pressure’s PCT technology helps researchers extract potential cancer biomarkers by employing alternating cycles of hydrostatic pressure to safely control biomolecular interactions. 

READ: Pressure BioSciences wins two more orders for its novel BaroShear K45 water-soluble CBD manufacturing system

The Chinese team from Westlake University in Hangzhou, which has purchased six PCT systems, published an article in 'Molecular Oncology' entitled “High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.”

In the piece, Westlake Laboratory Director Tiannan Guo explained PCT’s potential for analyzing the huge backlog of FFPE samples around the world. 

“We believe that the vast reservoirs of historical FFPE tissue samples accumulated in biobanks worldwide offer enormous potential using our methods for biomarker discovery, by leveraging the practicality and superiority of PBI’s PCT sample preparation platform for maximizing the diversity and abundance of results from FFPE samples,” Guo said. 

In the other article, from the Australian Cancer Research Center Foundation International Centre for the Proteome of Cancer (ProCan) entitled “Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: ProCan” was published in the journal 'Proteomics'.

Co-director Phil Robinson, who came away impressed with PCT’s results, said: “Our results from FFPE tissues following PCT sample preparation are consistent with other reports showing that high quality data can be generated and that the scale and scope of quantifiable proteins is comparable to that obtained from fresh frozen tissues.”

The Australian team has purchased six PCT systems since 2016.

Shares of Pressure BioSciences climbed 7.6% higher on Tuesday to $2.97.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Pressure BioSciences Inc.

Price: $3.24

Market: OTCQB
Market Cap: $6.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences CEO sees potential opportunity to enter...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical...

1 week, 4 days ago

2 min read